ScoreWhy is Emcure Pharmaceuticals Ltd ?
1
High Management Efficiency with a high ROCE of 21.82%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.84 times
3
Healthy long term growth as Net Sales has grown by an annual rate of 15.40% and Operating profit at 16.32%
4
Flat results in Mar 26
- CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 147.52 cr
- INTEREST(Q) Highest at Rs 46.40 cr
5
With ROCE of 22.8, it has a Expensive valuation with a 5.1 Enterprise value to Capital Employed
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 63.02%, its profits have risen by 38% ; the PEG ratio of the company is 0.9
6
Majority shareholders : Promoters
7
Market Beating Performance
- The stock has generated a return of 63.02% in the last 1 year, much higher than market (BSE500) returns of 5.38%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Emcure Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Emcure Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Emcure Pharma
63.02%
1.73
36.45%
Sensex
-3.74%
-0.28
13.48%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
15.40%
EBIT Growth (5y)
16.32%
EBIT to Interest (avg)
6.72
Debt to EBITDA (avg)
1.06
Net Debt to Equity (avg)
0.28
Sales to Capital Employed (avg)
1.30
Tax Ratio
26.87%
Dividend Payout Ratio
0
Pledged Shares
0.04%
Institutional Holding
9.45%
ROCE (avg)
19.51%
ROE (avg)
17.32%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
33
Industry P/E
35
Price to Book Value
6.26
EV to EBIT
22.36
EV to EBITDA
17.38
EV to Capital Employed
5.10
EV to Sales
3.52
PEG Ratio
0.87
Dividend Yield
0.18%
ROCE (Latest)
22.79%
ROE (Latest)
19.15%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
Bullish
Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
PAT(Latest six months)
At Rs 494.71 cr has Grown at 41.13%
ROCE(HY)
Highest at 22.47%
NET SALES(Q)
Highest at Rs 2,469.70 cr
-5What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 147.52 cr
INTEREST(Q)
Highest at Rs 46.40 cr
Loading Valuation Snapshot...
Here's what is working for Emcure Pharma
Profit After Tax (PAT) - Latest six months
At Rs 494.71 cr has Grown at 41.13%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 2,469.70 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Here's what is not working for Emcure Pharma
Interest - Quarterly
Highest at Rs 46.40 cr
in the last five quarters and Increased by 22.17 % (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 147.52 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
